Treximo’s review team determined that the PhlexSubmission software was the best fit to enhance the speed and quality of its customers’ regulatory submissions across drug, biologic, biosimilar, and medical device products. The expert review team was also impressed with Phlexglobal’s innovative application of technologies such as machine learning to enhance the speed and accuracy of the submissions process – freeing up Treximo and customer resources.
It also became clear that with Phlexglobal, Treximo could best support its goal of providing complete, responsive, and high-quality regulatory services to its customers, while effectively managing rapid growth.
“We’re honored that such an exceptional, customer-driven organization as Treximo recognized our shared values and passion to help our industry bring new therapies to market,” said John McNeill, Chief Executive Officer of Phlexglobal. “We look forward to supporting Treximo and its customers in this important, life-improving mission.”